芦可替尼对比最佳可用疗法治疗对羟基脲不耐受或耐药的ET
MAJIC-ET是一项随机2期试验,比较芦可替尼与最佳可用疗法(BAT)治疗对羟基脲耐药或不耐受的高危ET。改良意向治疗人群分别为58例和52例;1年内完全缓解率分别为46.6%与44.2%(P=.40);2年血栓、出血和转化率无显著差异,但芦可替尼组部分疾病相关症状改善;3/4级贫血和血小板减少在芦可替尼组更常见。
要点
- 芦可替尼1年完全缓解率46.6% vs BAT 44.2%,差异无统计学意义(P=.40)。
- 2年血栓、出血和转化率无显著差异,但芦可替尼组部分疾病相关症状改善。
- 芦可替尼组3/4级贫血19%、3/4级血小板减少5.2%和1.7%,BAT组均为0%。
核心结论
- MAJIC-ET试验提示芦可替尼并不优于当前ET的二线治疗。
研究设计与样本
- MAJIC(ISRCTN61925716)是一项随机2期试验,比较芦可替尼(JAK1/2抑制剂)与最佳可用疗法(BAT)治疗对羟基脲耐药或不耐受的ET和真性红细胞增多症患者。
- 本文报告MAJIC-ET结果,改良意向治疗人群包括随机接受芦可替尼的58例和接受BAT的52例患者。
主要发现
- 1年内完全缓解:芦可替尼组27例(46.6%)vs BAT组23例(44.2%),无改善证据(P=.40)。
- 2年时血栓、出血和转化率无显著差异;芦可替尼组部分疾病相关症状相对BAT改善。
- 分子学缓解不常见;CALR阳性芦可替尼治疗患者中2例完全分子学缓解(CMR)、1例部分分子学缓解;1例CMR患者转化为骨髓纤维化,推测因出现不同克隆。
- 3级和4级贫血:芦可替尼组19%和0% vs BAT组0%(两级别均0%);3级和4级血小板减少:芦可替尼组5.2%和1.7% vs BAT组0%(两级别均0%)。
- 两治疗组间停药或换药率无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatments for high-risk essential thrombocythemia (ET) address thrombocytosis, disease-related symptoms, as well as risks of thrombosis, hemorrhage, transformation to myelofibrosis, and leukemia. Patients resistant/intolerant to hydroxycarbamide (HC) have a poor outlook. MAJIC (ISRCTN61925716) is a randomized phase 2 trial of ruxolitinib (JAK1/2 inhibitor) vs best available therapy (BAT) in ET and polycythemia vera patients resistant or intolerant to HC. Here, findings of MAJIC-ET are reported, where the modified intention-to-treat population included 58 and 52 patients randomized to receive ruxolitinib or BAT, respectively. There was no evidence of improvement in complete response within 1 year reported in 27 (46.6%) patients treated with ruxolitinib vs 23 (44.2%) with BAT (P = .40). At 2 years, rates of thrombosis, hemorrhage, and transformation were not significantly different; however, some disease-related symptoms improved in patients receiving ruxolitinib relative to BAT. Molecular responses were uncommon; there were 2 complete molecular responses (CMR) and 1 partial molecular response in CALR-positive ruxolitinib-treated patients. Transformation to myelofibrosis occurred in 1 CMR patient, presumably because of the emergence of a different clone, raising questions about the relevance of CMR in ET patients. Grade 3 and 4 anemia occurred in 19% and 0% of ruxolitinib vs 0% (both grades) in the BAT arm, and grade 3 and 4 thrombocytopenia in 5.2% and 1.7% of ruxolitinib vs 0% (both grades) of BAT-treated patients. Rates of discontinuation or treatment switching did not differ between the 2 trial arms. The MAJIC-ET trial suggests that ruxolitinib is not superior to current second-line treatments for ET. This trial was registered at www.isrctn.com as #ISRCTN61925716.
引用
- Harrison CN, Mead AJ, Panchal A, et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017. PMID: 29074595. doi:10.1182/blood-2017-05-785790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。